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Abstract There is no data on reference gene (RG) selection in
metastatic clear-cell renal cell carcinoma (mccRCC) for quan-
titative PCR (qPCR) data normalization. We aimed at
selecting the most stable RG for further determination of
new prognostic markers. Thirty-five nonmetastatic and 35
mccRCC patients undergoing radical nephrectomy were in-
cluded. Paired primary tumor (T, n=70) and normal (C, n=70)
kidney fragments were collected; from 12 out of 35 mccRCC
cases, we also collected metastasized regional lymph nodes
and adrenal gland tissues (M, n=12). After RNA extraction,
reverse transcription and qPCR were performed. Samples
were divided into four analyzed groups. Fifteen candidate
RGs were tested by RefFinder tool and manual statistics. To
present the importance of RG selection, TP53 gene expression
levels in samples were normalized with the use of RG data.
RPL13 gene was the most stable RG in analysis of 35 primary
tumor nonmetastatic versus 35mccRCC samples andmatched
metastasized T/C/M samples (n=12, each group). GUSB was
the most suitable RG in total 152 samples and in paired T and
C (n=140) kidney samples. Expression ofGUSB, RPL13, and
the RPL13+RPLP0 pair were independent of clinical/sample
variables. Normalization of TP53 expression levels showed
variability of GAPDH and ACTB assays. GUSB or RPL13
assays should be used in mccRCC for qPCR data normaliza-
tion whereas GAPDH and ACTB assays should be avoided.
Prior RG studies should precede each qPCR gene expression
study since RG selection is associated with the origin and
proportion of specimens.
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Introduction
Renal cell carcinoma (RCC) is the third most common geni-
tourinary malignancy, and its incidence has increased in the
last 20 years [1]. The most frequent RCC subtype, clear-cell
renal carcinoma (ccRCC) is characterized by a very high
mortality rate of 40 %, due to distant metastases found in
30 % of RCC-diagnosed patients [2]. Although numerous
prognostic RCC markers have been proposed (e.g., Ki67,
TP53, CAIX) [3], there is an urgent need to perform gene
expression studies of tumor/metastatic RCC in order to find
new biomarkers [4]. Molecular analyses involve reverse tran-
scription (RT), followed by quantitative PCR (qPCR), and the
final expression results of target genes are based on normali-
zation to any stably expressed internal reference gene (RG),
measured in the same sample [5]. Expression level of a prop-
erly selected RG cannot be influenced by any clinical variable
of the analyzed specimens/patients, i.e., sample origin, disease
stage, or a pharmacological treatment [6, 7].
Most ccRCC gene expression studies are normalized to
GAPDH or ACTB genes [6], whose variable expression levels
were noticed in other malignancies [8–10]. Therefore, the first
aim of our study was to select the most stable RG among 15
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potential candidates in clinical material of primary
nonmetastasic and metastasic tumor ccRCC matched with
normal kidney tissue and ccRCC-origin metastasized tissues.
The second aim of the study was to analyze TP53 gene
expression rate with the use of obtained normalization data of
all RGs in order to show that the gene expression results in
ccRCC strongly depended on RG selection. The results of
such molecular approach have not been published yet.
Material and methods
Patients and samples
Tissue samples were collected from 70 patients with ccRCC
undergoing radical nephrectomy at the Department of
Urology of the Medical University of Gdansk (MUG),
Poland, between January 2011 and May 2013. The use of
tissue material was approved by the Medical Ethical
Committee of the MUG (decision no. NKEBN/4/2011), and
informed written consent regarding the use of tissue was
obtained before surgery from each ccRCC patient. One hun-
dred fifty-two samples were classified into four groups as
shown in Fig. 1. Thirty-five ccRCC cases did not show
metastases at the time of nephrectomy whereas local and
distant metastases were diagnosed in 35 ccRCC patients (me-
tastasized ccRCC; mccRCC); five mccRCC cases showed
distant metastasis: lung (n=2), brain (n=2), brain and liver
(one patient) (Table 1). Other mccRCC patients possessed
metastases located in regional paracaval or paraaortic lymph
nodes. Metastases were also diagnosed in adrenal gland and
vein thrombus. From all 70 patients, primary tumor (further
named as “T”) and corresponding noncancerous fragments
(named as “C”) of the kidney were obtained. Additionally,
from 12 mccRCC patients, apart from tumor and kidney
tissue, we also collected metastasized tissue samples (named
“M”) from regional lymph nodes and adrenal glands (n=10
and n=2, respectively) due to additional lymphadenectomy
and/or adrenectomy performed during nephrectomy (Fig. 1);
metastasized tissue specimens from remaining 23 mccRCC
cases were not obtained for this study. There was a positive
correlation between TNM stage grouping and Fuhrman’s
nuclear grades, rs=0.52, P<0.001, Spearman’s test.
Material acquisition
The dissected tissue samples of primary ccRCC tumor, normal
kidney, and adrenal gland (ca. 7±2 mm×7±2 mm×7±2 mm)
or the whole lymph node (ca. 10 mm×10 mm×10 mm) were
collected in the operating room no longer than 20min after the
kidney resection and placed in approximately five volumes of
RNAlater (Ambion Inc., Austin, TX, USA). Three sectioned
pieces of each sample were made. The central piece was used
for RNA extraction, while the two side pieces were fixed in
formalin and embedded in paraffin, followed byH&E staining
and the examination performed by pathologist.
RNA extraction and DNA digestion
Total RNA isolation was performed using GeneMATRIX
Universal RNA Purification Kit (Eurx, Gdansk, Poland).
Briefly, the tissues were homogenized in 2-ml tubes with
ceramic beads (Blirt, Gdansk, Poland) in the presence of
300 μl lysis buffer (Eurx) in the MagnaLyser apparatus
(Roche Diagnostics Deutschland GmbH, Mannheim,
Germany) for 45 s at 6,000 rpm. Further processing was
performed following the manufacturer’s (Eurx) protocol.
Isolated RNA was eluted with 70 μl of nuclease-free water
(Eurx), followed by quantification with spectrophotometer
(Nanodrop ND 1000, Thermo Fisher Scientific, Fitchburg,
WI, USA). The RNA integrity and quality were characterized
by RNA integrity number (RIN) with the RNA 6000NanoKit
using the Eukaryote Total RNA Nano Chip and Bioanalyzer
2100 apparatus (Agilent Technologies, Santa Clara, CA,
USA). Next, 20 μl of extracted RNA was treated with
TURBO DNA-free kit (Ambion) according to manufacturer’s
protocol.
First-strand cDNA synthesis
Complementary DNAs (cDNAs) were polymerized from 2 μg
total RNA (100 ng RNA/1 μl RT reaction) of each sample
using 0.5 μg oligo(dT)18 primers (Sigma-Aldrich, Munich,
Germany), 200 U RevertAid Reverse Transcriptase, 1 mM
dNTP mix, and 2 U Ribo-Lock (Fermentas-Thermo Fischer
Scientific, Fitchburg, WI, USA). RT reaction was performed
according to manufacturer’s protocol, and the resulting cDNA
was stored at −25 °C after 10× dilution with nuclease-free
water to be used as the template in qPCR analysis.
Design and validation of reference gene primers
The primers were designed using Primer-BLAST software.
The calibration curves for all gene-specific qPCR assays were
performed (data not shown), and the resulting calibration
curves’ data are presented in Table 2.
The selection of RG assays for this study was based on the
following: MeSH database search for the most commonly used
RGs in ccRCC and in other cancers; previous literature results
of normalization studies of kidney and other cancers [6, 10–14]
and the commercially available RG sets (Roche Diagnostics,
SA Biosciences, Life Technologies/Applied Biosystems).
For the RGs assays, the 15-μl reaction mixture included
1.5 μl 10× diluted sample cDNA, 0.2 μM each forward and
reverse primers and SensiFast Sybr™ No-Rox kit (Bioline,
London, UK). qPCR reactions for all RGs were performed in
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triplicate in StepOne Plus apparatus (Life Technologies/
Applied Biosystems, Grand Island, NY, USA), and the geo-
metric mean of cycle threshold (Ct) values was used in further
analyses with StepOne Software ver. 2.2 (Life Technologies/
Applied Biosystems). We set runs for each gene assay sepa-
rately. Each qPCR run contained paired T/C or T/C/M
samples, no-template control (water instead of cDNA), and
10× diluted pooled cDNA as a run-to-run precision control.
Intra-run and inter-run precision control tests were set using
10× diluted pooled cDNA in the same conditions as routine
RGs assays. The intra-batch control was based on qPCR
reactions for GUSB assay in 15 replicates during the same
Fig. 1 Sample origin and division into groups. Seventy patients under-
going radical nephrectomy were characterized by the local or distant
metastases diagnosed in 35 cases (metastatic, mccRCC group) and 35
were nonmetastatic at the time of surgery. Shaded color represents normal
kidney, black pattern represents primary tumor, and white-dotted black
pattern shows regional metastasis to adrenal gland, paraaortic, and
paracaval lymph nodes. Primary mccRCC tumors were characterized
by the cancer spreading beyond Gerota’s fascia or into large veins (not
shown tomake figure lucid). From 12mccRCC patients, the metastasized
tissues were collected (arrows point example tissues), and together with
matched primary tumor and normal kidney samples, group IV was
created
Table 1 Demographic and pathologic classification of ccRCC patients










Age (years)a 60.97±12.05 60.57±13.41 61.37±10.68 61.42±6.86
Sex (M/F) 41/29 20/18 21/11 8/4
Tumor location Left/right kidney 34/36 23/12 11/24 5/7
Fuhrman’s histological grade 1 4 (6) 4 (11.4) – –
2 35 (50) 25 (71.2) 10 (28.5) 2 (17)
3 19 (27) 4 (11.4) 15 (43) 8 (66.6)
4 12 (17) 2 (6) 10 (28.5) 2 (17)
TNM stage grouping Nonmetastatic T1-2N0M0 30 (43) 30 (86) – –
T2N0M0 5 (7) 5 (14) – –
Metastatic T1-2N1M0 T3N0-1M0 30 (43) – 30 (86) 10 (83)
T4N0-2M0T1-4N2M0
T1-4N0-2M1
5 (7) – 5 (14) 2 (17)
a Data shown as mean±SD
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run. Inter-batch (run-to-run) test was based on data obtained
from separate runs (n=5) as described above, for each RG
assay separately. In both tests, raw Ct data were collected and
mean±standard deviation (SD) values were computed. Ct
coefficient of variation (CtCV%) values were calculated using
the following formula: CtCV=SD/mean×100 %.
The gene TP53 which was targeted for normalization in
ccRCC was amplified using the same conditions as RGs
(details in Table 2).
Immunohistochemistry (IHC) methodology for TP53 pro-
tein is presented in supplementary materials.
Data analysis
Statistical analysis
Raw Ct data was transferred and calculated using GraphPad
Prism, ver. 6.05 (GraphPad Software, San Diego, CA, USA).
Normality of qPCR and clinical data was checked using D’
Agostino and Pearson omnibus test. Nonparametric Mann-
Whitney U (A) and Kruskal-Wallis ANOVA tests (B) were
used to compare clinical and qPCR data.
Selection of single reference gene with the use of specialized
tools
The free online software tool, RefFinder [15] was applied,
which uses the following algorithms: BestKeeper [16],
NormFinder [17], GeNorm [7], and the relative delta Ct
(dCt) [18] method. The final ranking from 1 (best RG) to 15
(least suitable RG) was shown as a result.
Selection of RG pair
GeNorm data for a pair of RG was transferred from RefFinder
results. For NormFinder RG pair selection, raw Ct data were
calculated into arbitrary units (AU) with the use of calibration
curves data (Table 2).
Association of RG expression and clinical data
Raw Ct qPCR data of RG assays were compared with differ-
ent clinical variables (Table 1) with the use of statistical tests
described above (A or B).
RGs expression level versus sample origin
Raw Ct data for each RG assay were divided according to the
sample origin (T, C, or M) and analyzed group (I–IV); statis-
tical association between samples’ Ct values were assessed
using A or B tests.
Gene normalization based on RG data
The expression of TP53 was calculated using raw Ct data
normalized with the use of Ct data of each RG. Further,
expression data of TP53 in control samples was set to 1 and
the expression of TP53 in T and M samples were calibrated to
results obtained in control samples.
Results
RNA quality control
The average RNA concentration was 379.51±222.21 ng/μl
(range 76.00–1,980.60 ng/μl). All samples presented high
RNA quality and integrity; mean A260/280 ratio was 2.02±
0.07 (range 1.96–2.13); average RIN values from all samples
were 8.32±1.12 (range 5.5–9.8).
Intra- and inter-batch qPCR precision control
As a part of a validation procedure of the presented qPCR
method [19–21], pooled cDNA (10× diluted) from all samples
was used as precision control material for each RG assay run.
For intra-batch precision test mean Ct±SD was 25.12±0.247;
therefore, CtCV% value was 0.98 % for GUSB assay
(Supplementary Fig. 1). The inter-batch precision values of
CtCV% ranged from 0.37 % for GUSB to 0.74 % for HMBS
(details not shown). Obtained results fulfill the precision
criteria of bioanalytical method validation (CtCV%<15 %)
[19, 22].
Selection of a single RG
Raw Ct data of all RGs assays (Supplementary Fig. 2) were
analyzed by RefFinder [15]. The results for analyzed groups
of samples (Fig. 1) are shown in Fig. 2. Since RefFinder
utilizes summary results obtained from dCt, BestKeeper,
GeNorm, and NormFinder, a brief presentation of each tool
with results are described below.
Relative delta Ct
dCt method was applied by Silver et al. [18] and is based on
the mean SD value calculated between Ct data of each tested
RG in comparison to other assays (e.g., GUSB vs ACTB,
followed by GUSB vs GAPDH); RG assay with the smallest
SD number is judged as the most stable. GUSB was the most
stable RG in group I (all samples),GAPDH in group II (paired
70 T+70 C), followed by RPL13 in groups III (35
nonmetastatic vs 35 mccRCC) and IV (matched tumor-
metastasized control group of samples).
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BestKeeper
The tool utilizes statistical calculations of each RG assay
separately; RG with both smallest SD and Pearson’s correla-
tion coefficient values is considered as the most stable [16].
BestKeeper rankedGUSB as themost stable in groups I and II,
whereas RPL13 and RPL32 were selected as best RGs in
groups III and IV, respectively (Supplementary Table 1).
NormFinder
NormFinder utilizes a special algorithm which combines
group division, absolute copy number of gene, and variation
caused by biological and experimental factors [17]. Therefore,
raw Ct data had to be computed into AU by our team (see
“Materials and methods” section) before NormFinder analy-
sis. This algorithm selected GUSB as the best single RG in
groups I and II and RPL32 and RPL13 in groups III and IV,
respectively. NormFinder’s RGs pair selection are presented
further.
GeNorm
GeNorm calculates a normalization factor (M) based on a
geometric mean of Ct values of at least two RGs. Stepwise
exclusion of the least stable gene allowed the genes to be
ranked according to the stability value (the lower the M value,
the higher the gene’s expression stability) [7]. RefFinder’s
Fig. 2 Summary selection of best single RG or RG pair with the use of
RefFinder, GeNorm, and NormFinder. a All samples (n=152), b paired
primary tumor and control kidney samples (n=140), c primary
nonmetastatic and mccRCC tumor samples (n=70), d metastatic group
with matched tumor, normal, and metastatic samples (n=36). Dark gray
bar shows the best single RG whereas chequered pattern shows the least
stable genes in the analysis. Light gray bars depict RG pair selected by
NormFinder (with stability value of the pair), while left diagonal bars
represent GeNorm RG pair (with stability value of the pair)
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built-in GeNorm algorithm chose a combination of two can-
didate RGs with the lowest M values, and the results are
shown in Fig. 2.
RefFinder summary ranking of a single RG
RefFinder, free online tool, combines results of the mentioned
single-RG algorithms. Besides RefFinder’s availability and
simplicity (copy-paste of raw Ct data staged in columns), the
more RGs are tested, the more precise result is obtained.
Figure 2 and Supplementary Table 1 show RefFinder ranking;
GUSB was selected as the best RG in groups I and II, and
RPL13 was the most suitable gene in groups III and IV.
Selection of RG pair
Due to recommendation to use at least two normalizers for
gene expression analysis instead of one [5, 20], GeNorm and
NormFinder results were applied. Due to differences in algo-
rithms, no common scores between tools for any analyzed
group of tissues (linked RGs in Fig. 2) was observed (with one
exception; GAPDH + PPIAwas selected by GeNorm as best
pair in groups I and II). As a result we selected seven different
RG pairs in four sample groups. In order to clarify this
disagreement, we found that the CtCV% factor has been
recommended to validate NormFinder and GeNorm results
[23]. We checked CtCV% values for all selected RG pairs
together with single RGs in different groups (Supplementary
Table 2) and observed that NormFinder’s selections were
characterized by lower CtCV% values than GeNorm’s
choices. Although such result shows that RGs pairs selected
by NormFinder are more stable than GeNorm’s pairs, we also
found that for groups I–II, the best single RG showed lower
CtCV% value than for any RG pairs (6.58 and 6.19 % for
GUSB vs 8.21 and 8.36 % for NormFinder’s pair for groups I
and II, respectively, Supplementary Table 2).Moreover, single
RG for groups III and IV—RPL13 presents CtCV% value
between pairs of NormFinder and GeNorm. Based on those
results, we suppose that despite RG pairs selected by
NormFinder better meet the statistical requirement than
GeNorm’s, they do not outdistance single RG selection.
Relationship of RGs expression and experimental variables
Apart from selection of the most stable gene in selected groups
with the use of specialized tools, the final result of RG selec-
tion has to be supported by manual statistics which utilize
clinical variables and material division into subgroups accord-
ing to their origin [6, 10, 14]. Only genes which are complete-
ly independent of those variables (in statistical perspective;
P>0.05 between subgroups) can be finally chosen as a suit-
able RG in selected group of samples.
Association between RGs level and clinical status of ccRCC
patients
Single RGs qPCR data of all 152 samples (Supplementary
Fig. 2) were compared to clinical data of the ccRCC patients
(Table 1). We also added comparison of RG pairs selected by
GeNorm or NormFinder algorithms; the statistical results are
shown in Table 3. The expression of any genes or RG pairs
was not associated with gender and age of patients.
Interestingly, we observed that GAPDH, GUSB, IPO8,
RPL13, RPL32, and UBC genes, as well as RPLP0+TBP,
RPL13+RPL32, RPL13+RPLP0, and ACTB+TBP RG pairs,
were the only assays whose expression did not depend
(P>0.05) on cancer progression. Since the expression levels
of remaining RGs were associated with at least one selected
clinical factor, they should not be further included in normal-
ization panel of ccRCC studies (Table 3).
Analysis of RG expression in subset of biopsies
Expression data of each single RG in 152 samples were
divided into groups I–IV, followed by statistical comparison
according to their origin; e.g., expression levels of 70 T versus
70 C for group II. Summary plots are presented in Fig. 3. We
observed that the higher the sample heterogeneity occurs in
analyzed group, the fewer the genes share similar (origin-
independent; P>0.05) expression pattern between subgroups;
if 70 T versus 70 C (group II) were assessed, expression
pattern of six genes was comparable (Fig. 3b, P>0.05)
in comparison to group I with only four genes when
12 M subgroup was introduced. We therefore observed
the highest similarity between RG expression levels
between samples when nonmetastatic versus metastatic
tumor specimens were compared (group III, Fig. 3c). As
a result, candidate genes which passed this statistical
test can be considered in final RG result in selected
groups of samples.
Comparable statistical analyses were performed for seven
RG pairs selected by GeNorm and NormFinder (Fig. 4). We
observed that only GAPDH+RPL13 and RPL13+RPLP0
pairs share similar expression levels in groups III and IV,
respectively; therefore, other RG pair should be omitted from
the final selection.
Impact of reference gene on the relative expression of TP53
gene
The expression analysis of the target gene TP53 were used in
this study to demonstrate the effect of different normalization
genes on the relative expression data (Fig. 5a, b). For paired
tumor and normal samples (group II), we observed increased
expression of TP53 if ACTB, B2M, GAPDH, or RPLP0 were
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used for normalization. We also observed that for the
least suitable RGs (chequered bars in Fig. 5a), there
were no statistically significant differences between T
and C samples.
When the matched 12 T/C/M samples were investigated
(Fig. 5b), the expression pattern of TP53was different than for
the 70 T/C group, i.e., we observed decreased TP53 expres-
sion in T samples for 11 of 15 RGs, including ACTB and
GAPDH, as well as when GeNorm and NormFinder RG pairs
were used for normalization (P<0.05, Fig. 5b).
Based on a well-documented decreased expression pattern
of TP53 gene in ccRCC tumor samples [24, 25], we decided to
apply candidate RGs which showed significant under expres-
sion of TP53 in tumor samples in both normalization ap-
proaches (group II and group IV). Therefore, only GUSB,
IPO8, PPIA, and RPL13 genes, as well as PPIA+RPL13,
RPL13+RPLP0, and ACTB+TBP pairs, passed this test. The
different levels of TP53 expression for ACTB, GAPDH, and
B2M in relation to number of analyzed cases should exclude
those genes from RG panel for ccRCC, since the expression
results of TP53 cannot change by the increased number of
analyzed samples (i.e., under expression of TP53 when 12 T/
C were selected versus overexpression of TP53 when 70 T/C
was analyzed). We also observed only small increase of TP53
expression (ca. 2× increase vs control) in metastasized sam-
ples when GAPDH was utilized for normalization in contrast
to 10× higher expression when RPL13 was used as RG
(Fig. 5b).
Additionally, we checked the presence of TP53 protein in
matched biopsies of T/M/C samples (group IV) with the use of
immunohistochemistry (IHC, supplementary methods). IHC
staining showed high expression of TP53 in normal kidney,
with its dispersed distribution in the cytoplasm of epithelial
cells. On the contrary, in tumor ccRCC slides, we observed a
high accumulation of TP53 mainly in the nuclei of malignant
cells (Fig. 6e–h). Moreover, we observed massive presence of
TP53 protein in all metastasized and normal immune cells of
lymph nodes (Fig. 6c, d), which was in accordance with
upregulation of TP53 mRNA (Fig. 5b) in metastasized
samples.
Table 3 Statistical relationship between data of ccRCC patients and qPCR data of single reference genes and RG pairs
Gene pair Sex Age TNM stages Nonmetastatic vs metastatic
ccRCC (TNM stages grouped)
Fuhrman’s histological grade (1–4)
ACTB ns ns ns ns 0.04
B2M ns ns ns ns 0.0026
GAPDH ns ns ns ns ns
GUSB ns ns ns ns ns
HMBS ns ns 0.0066 0.033 ns
HPRT1 ns ns ns ns 0.002
IPO8 ns ns ns ns ns
PGK1 ns ns <0.0001 0.001 0.0075
PPIA ns ns ns ns 0.003
RPL13 ns ns ns ns ns
RPL32 ns ns ns ns ns
RPLP0 ns ns 0.0046 0.002 ns
TBP ns ns 0.0001 0.0029 0.0003
TFRC ns ns ns ns 0.0026
UBC ns ns ns ns ns
GAPDH+PPIAa ns ns 0.0011 0.0011 ns
RPLP0+TBPb ns ns ns ns ns
PPIA+RPL13b ns ns 0.0012 0.0005 0.02
GAPDH+RPL13a ns ns 0.0245 0.011 ns
RPL13+RPL32b ns ns ns ns ns
RPL13+RPLP0a ns ns ns ns ns
ACTB+TBPb ns ns ns ns ns
Ct data was calculated as geometric mean of each assay. Statistical tests used: Mann-Whitney U test—sex, nonmetastatic (T1-2N0M0 + T2N0M0)
versus metastatic (T1-2N1M0, T3N0-1M0 + T4N0-2M0, T1-4N2M0, T1-4N0-2M1) ccRCC; Kruskal-Wallis ANOVA—age, TNM stage, Furhman’s
histological grade (1–4). P<0.05. ns: P>0.05. Ct data were used for statistical comparisons
a RG pair as selected by GeNorm for groups I–IV
b RG pair as selected by NormFinder for groups I–IV
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Reference gene final selection
Based on single reference gene selection (RefFinder) together
with exclusion results of clinical/biological versus RG expres-
sion statistical tests, as well as TP53 normalization approach,
we found thatGUSB is the most suitable single RG for groups
I and II and RPL13 is best RG for groups III and IV (Table 4).
Different pattern occurs for RG pair selection, since only
RPL13+RPLP0 selected by the GeNorm algorithm (Table 5)
fulfils statistical criteria; therefore, for matched tumor-control-
metastasized ccRCC samples (group IV) RPL13+RPLP0 pair
may be considered for normalization in gene expression
studies.
Discussion
In this study, we presented methods and results of selection of
suitable RGs in metastatic ccRCC, because currently, there is
no data concerning this important issue. A reliable
normalization project should be based on validation proce-
dures related to analytical biochemistry [6, 19]. Since the
presented data contain standardization of sample preparation
and RNA integrity assessment, followed by qPCR require-
ments [5, 20]—standard curve, precision tests (intra- and
inter-run), and selectivity (melt curve)—we believe that our
methodology and results can be utilized by other researchers.
To date, only three groups performed similar RG selection
studies on tumor ccRCC compared to normal kidney tissue [6,
26, 27], while Bjerregaard et al. focused on ccRCC versus
renal oncocytoma [10]. When compared with the mentioned
data, our study was based on nonmetastatic versus mccRCC
cases and analyzed the highest number of RGs. Although
RGs’ suitability was calculated and ranked with the use of
specialized tools, the limitation of those algorithms is the
utilization of raw expression data without consideration for
either clinical data or sample’s primary localization.
Therefore, the statistical comparison of clinical or specimen’s
origin versus expression data had to be evaluated with the use
of manual statistics, since one of the basic requirement for RG
Fig. 3 Expression levels of candidate reference gene assays in analyzed
groups divided by sample origin. Summary results of all RG assays (x
axis) and Ct data (y axis). Box (median Ct and lower and upper quartiles)
and whisker (10–90 % Ct values) plot for each samples’ subgroup. a All
samples (n=152), b paired primary tumor and control kidney samples (n=
140), c primary nonmetastatic and mccRCC tumor samples (n=70), d
metastatic group with matched tumor, normal, and metastatic samples (n=
36). Statistics used: a, d—Kruskal-Wallis ANOVA; b, c—Mann-Whitney
U test. *0.01<P<0.05; **0.001<P<0.01; ***P<0.001; ns, P>0.05 be-
tween subgroups
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selection is the independence of expression from biological
and clinical variables [6, 7]. We therefore observed the inde-
pendence of suitable RGs’ expression from clinical factors,
which was in accordance with other authors’ observations [6,
27, 28].
Our results of RG selection are not in agreement with other
authors who focused on RCC. Although Jung et al. found
TBP+PPIA as the most suitable RG pair, their study on 25
cases introduced 24/1 male/female (M/F) and no patients with
diagnosed metastasis, whereas our project contained larger
population sample (41/29 M/F) and 35 mccRCC (T3 or N1-
2 or M1) cases. The most recent report on RG selection in
ccRCC shows that PPIA and RPS13 (or their combination) is
based on paired tumor control kidney specimens (no metasta-
sized tissue) from 16 (14/2 M/F) ccRCC patients [27].
Furthermore, only 5 of 16 patients from the Dupasquier
et al. study presented local or distant metastases [27].
Finally, in contrast to utilization of the same algorithms and
manual statistics, ours and the mentioned studies data cannot
be strictly compared, since they did not check stability of
GUSB or RPL13 genes [6, 27].
The limitation of our study is, however, the lack of distant
metastasized samples (bone, lung) and utilization of only 12
samples obtained from regional metastases. Therefore, our
findings should be confirmed by independent studies per-
formed by other teams.
Our results also contained the selection of RGs pair.
Although the use of two or more RGs in gene expression
studies has been strongly recommended by minimum infor-
mation for publication of quantitative real-time PCR experi-
ments (MIQE) guidelines [20], cancer gene expression studies
rarely utilize more than one RG for the normalization [29–31].
In fact, the most recent review which focused on observance
ofMIQE in qPCR gene expression studies in colorectal cancer
revealed that only 6 of 179 (3.3 %) analyzed studies (between
2006 and 2013) used two RGs [21]. Therefore, we do not
suppose that the requirement for two or more RGs in gene
expression studies is also followed in ccRCC; hence, we
propose to use one but carefully selected RG.
Additionally, despite the fact that GeNorm tool offers
the evaluation of a number of RGs recommended for
normalization (two or more RGs), we did not find any
reference which uses three or more RGs in cancer gene
expression studies. Finally, since no common results
were found between individual algorithms or groups’
divisions, followed by statistical failure of most selected
RGs pairs, we propose to focus on single-RG
normalization.
Fig. 4 Expression levels or candidate reference gene pairs in specimens’
subgroups. RG pairs were selected by either GeNorm or NormFinder
algorithms, separately for each analyzed group. Ct data were calculated
using geometric mean of Ct score for each gene. Figure legends according
to Fig. 3
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We chose to create different analyzed groups of samples
and presented complex results based on this division. It was
connected to the fact that we utilized a large number of
specimens; therefore, we decided to present as much useful
data as possible. Although the presentation of more than only
one comparison (nonmetastatic vs metastatic tumor samples)
[14] could be obscured, our results for more groups can be
easily utilized by other teams working on different origin of
samples, e.g., paired tumor control samples for studies of
ccRCC cancer development markers.
Our normalization approach of TP53 gene expression has
clearly shown that the choice of an appropriate reference gene
can strongly affect final results of gene expression studies. We
chose the TP53 tumor suppressor gene, whose decreased
expression in tumor samples of ccRCC and other
malignancies was proven by other studies [24, 25, 32, 33].
Apart from other presented statistical results in this study, we
propose to exclude GAPDH and ACTB from the normaliza-
tion panel, since false results can be obtained when normal-
ized to those RGs. AlthoughGAPDH is the most common RG
in RCC studies and most author may disagree with our results,
GAPDH expression stability should also be questioned when
the biological characteristics of RCC is taken into consider-
ation. Since tumor RCC is characterized by dysregulation of
glucose metabolism [34], it is a strong support for nonconstant
expression of GAPDH [23]. Moreover, it was noted that
GAPDH protein level changes in RCC aswell in other cancers
[9]. Our results of TP53 normalization in metastasized group
with the use ofGAPDH versus RPL13 reinforced the variabil-
ity of GAPDH, since we confirmed strong overexpression of
Fig. 5 Normalization of TP53
gene expression with the use of
RG data. In selected groups II and
IV, the expression of TP53 for
control samples (70 and 12 C)
were set to 1 and expression
values in the matched tumor (70
T) or tumor and metastasis (12
T/M) were calculated as
multiplies. The columns represent
the median and interquartile
ranges of the TP53 gene
expression. Dark gray bars
represent the most stable single
RG selected for the analyzed
specimens’ group; chequered
pattern shows the least stable
genes in the analysis, according to
RefFinder results. Light gray bars
show the relative expression
normalized to geometric mean of
RG pairs selected byGeNorm and
NormFinder algorithms,
respectively. a Relative
expression in paired 70 T samples
in relation to 70 C specimens
(expression set to 1). b Relative
expression in matched 12 T
(blank) and 12 M (dotted boxes)
in relation to 12 C specimens.
*P<0.05 between TorM samples
and control (Wilcoxon test),
αP<0.05 between matched T and
M samples (Wilcoxon test).
Please note that results for 70 T
(a) and 12 M (b) cannot be
directly compared due to different
control groups
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TP53 in metastasized tissues (as calculated with the use of
RPL13) by IHC, as well as other authors found its increase
expression in this type of samples [3, 35]. This point is another
limitation of our study, since the RNA in situ hybridization
(RNA ISH) should be applied in order to show the TP53
mRNA content in cells instead of protein and confirm the
results obtained by qPCR method. Since this method is cur-
rently unavailable to our team (i.e., RNA ISH requires differ-
ent sample preparation [36]), we aimed to confirm the general
TP53 expression pattern in tumor-control-metastasized
ccRCC samples by the means of IHC.
In comparison to GAPDH, GUSB and RPL13 proteins do
not seem to be involved in ccRCC development, since GUSB
is not engaged in intracellular metabolism, whereas RPL13 is
highly expressed in the cytoplasm of all nucleated cells. Due
to high stability, GUSB was noted as a suitable RG in lung
[37] and ovarian [38] cancers, whereas RPL13 was the best
RG in Alzheimer’s disease [39] and in mesenchymal stem cell
study [40]. We suppose that last reference is a key to the
observed highest stability of RPL13 in groups III–IV and
may be caused by the high proportion of poorly developed
(highly aggressive, Fuhrman’s stage 3–4) cells of tumor spec-
imens in analyzed groups, which can be characterized by the
increase deregulation or cellular machinery as compared to
other specimens. Furthermore, the high differences in RG
results between groups I–II and III–IV may be connected to
the high proportion of metastatic tumor samples—from one
fourth in group II to one half in group III, as well as to the
Fig. 6 Representative histological and immunohistochemical pictures of
ccRCC patient’s tissue (male, 73 years, Fuhrman grade 4, pT3aN1Mx).
Hematoxylin and eosin staining of ccRCC metastasis to perirenal lymph
node a ×100, b ×400). Arrow shows metastasized cells with clear-cell and
eosinophilic RCC pattern (dotted arrow). c, d IHC staining for TP53
protein presents high accumulation of protein in cytoplasm of immune
cells (dotted arrow) and lower accumulation in cytoplasm ofmetastasized
cells (solid arrows). d The presence of TP53 is limited mostly to nuclei of
malignant cells; no TP53 presence in lymph node trabeculae (dotted
arrow). e, f Normal kidney’s cortex fragment stained for TP53; the very
high presence of TP53 is found in the cytoplasm of podocytes and tubular
cells. g, h IHC staining for TP53 in tumor ccRCC; the protein is limited
mostly to nuclei of malignant cells. i Negative control (without primary
Ab, only hematoxylin staining) for TP53 in ccRCC (×400); obviously big
and irregular shape of nuclei with up to five visible nucleoli indicate
Furhman’s grade 4. Please note that high accumulation of TP53 in h
obscures the nuclei details found in i
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introduction of metastatic tissue samples in group IV. We
wanted to emphasize this factor, because not only the different
type but also the proportion between the numbers of samples
of different origin have strong influence on RG selection.
Table 4 Final selection of a single RG in ccRCC groups based on summary data of normalization algorithm and manual statistics
Pass—expression level of RGwas nonsignificantly different between sample subgroups (P>0.05) in group division; independent of some clinical factor
(P>0.05); or TP53 was statistically decreased (P<0.05) in tumor samples when normalized to selected RG. Empty cells—RGs which did not fulfill the
mentioned statistical criteria. Pale gray cells—the most suitable and common scores for specific RG






















Pass—expression level of RGs pair was nonsignificantly different between sample subgroups (P>0.05) in group division; independent of some clinical
factor (P>0.05); or TP53 was statistically decreased (P<0.05) in tumor samples when normalized to selected RGs pair. Empty cells—RGswhich did not
fulfill the mentioned statistical criteria. X—test was not assessed for a selected pair. Pale gray cells—the most suitable and common scores for specific
RGs pair
a GeNorm RG pair selections for different groups
bNormFinder RG pair selections for different groups
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Conclusions
For gene expression studies of mccRCC, we recommend to use
a single RG (GUSB or RPL13) and to avoid the following RGs
for normalization: ACTB, B2M, GAPDH, TFRC, and UBC.
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